Review



serum igf1 concentration  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    R&D Systems serum igf1 concentration
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Serum Igf1 Concentration, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 383 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/serum igf1 concentration/product/R&D Systems
    Average 99 stars, based on 383 article reviews
    serum igf1 concentration - by Bioz Stars, 2026-03
    99/100 stars

    Images

    1) Product Images from "Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1."

    Article Title: Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1.

    Journal: Cell communication and signaling : CCS

    doi: 10.1186/s12964-024-01472-6

    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1). A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Figure Legend Snippet: Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1). A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)

    Techniques Used: Staining, Expressing, Control

    Fig. 4 Effects of prenatal dexamethasone exposure (PDE) on postnatal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1) at postnatal week (PW) 6 and 12. A The mRNA expression of liver development-related genes at PW6 (n = 8); (B) Serum CORT at PW6 (n = 8); (C) Serum IGF1 level at PW6 (n = 8); (D) The mRNA expression of liver IGF1 signaling pathway expression at PW6 (n = 8); (E) Serum CORT with or without unpredictable chronic stress (UCS) at PW12 (n = 8); (F) Serum IGF1 level with or without UCS at PW12 (n = 8); (G) The mRNA expression of liver IGF1 signaling pathway expression with or without UCS at PW12 (n = 8); (H) The mRNA expression of liver development-related genes with or without UCS at PW12 (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/kg∙d)
    Figure Legend Snippet: Fig. 4 Effects of prenatal dexamethasone exposure (PDE) on postnatal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1) at postnatal week (PW) 6 and 12. A The mRNA expression of liver development-related genes at PW6 (n = 8); (B) Serum CORT at PW6 (n = 8); (C) Serum IGF1 level at PW6 (n = 8); (D) The mRNA expression of liver IGF1 signaling pathway expression at PW6 (n = 8); (E) Serum CORT with or without unpredictable chronic stress (UCS) at PW12 (n = 8); (F) Serum IGF1 level with or without UCS at PW12 (n = 8); (G) The mRNA expression of liver IGF1 signaling pathway expression with or without UCS at PW12 (n = 8); (H) The mRNA expression of liver development-related genes with or without UCS at PW12 (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/kg∙d)

    Techniques Used: Expressing, Control

    Fig. 6 Effects of prenatal dexamethasone treatment (PDT) on the body weight, serum hepatic function markers, serum cortisol level, and serum insulin-like growth factor 1 (IGF1) level of the male neonates. A Neonatal body weight (n = 18); (B) Serum albumin (ALB) (n = 18); (C) Serum alpha-fetoprotein (AFP) (n = 18); (D) The ratio of ALB to AFP (n = 18); (E) Serum cortisol level (n = 18); (F) Serum IGF1 level (n = 18); (G) The correlation analysis between serum cortisol and IGF1; Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance
    Figure Legend Snippet: Fig. 6 Effects of prenatal dexamethasone treatment (PDT) on the body weight, serum hepatic function markers, serum cortisol level, and serum insulin-like growth factor 1 (IGF1) level of the male neonates. A Neonatal body weight (n = 18); (B) Serum albumin (ALB) (n = 18); (C) Serum alpha-fetoprotein (AFP) (n = 18); (D) The ratio of ALB to AFP (n = 18); (E) Serum cortisol level (n = 18); (F) Serum IGF1 level (n = 18); (G) The correlation analysis between serum cortisol and IGF1; Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance

    Techniques Used: Control

    Fig. 7 Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1. GC, glucocorticoid; GRα, glucocorticoid receptor α; SP1, special protein 1; IGF1, insulin-like growth factor 1; H3K27ac, histone 3 lysine 27 acetylation
    Figure Legend Snippet: Fig. 7 Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1. GC, glucocorticoid; GRα, glucocorticoid receptor α; SP1, special protein 1; IGF1, insulin-like growth factor 1; H3K27ac, histone 3 lysine 27 acetylation

    Techniques Used:



    Similar Products

    94
    Multi Sciences (Lianke) Biotech Co Ltd human sputum igf1 concentration detection
    a UMAP plots of 12 macrophage and DC subtypes from baseline and follow-up samples. <t>IGF1</t> ⁺Macrophage cluster (cluster 3) highlighted. b Volcano plot of DEGs in IGF1 ⁺ macrophages between baseline and follow-up. Upregulated (red), downregulated (blue), stable (grey) genes shown. c Bar plots of top enriched Reactome pathways in IGF1 ⁺ macrophages from DEGs (two-sided Wilcoxon rank-sum test, adjusted P values). Pathway enrichment of top 20 upregulated genes via Enrichr (Reactome_Pathways_2024, hypergeometric test, unadjusted P values). d UMAP plots of key marker gene expression ( HP , IGF1 , RETN ) in macrophage subsets; color intensity reflects normalized UMI counts. e Violin plots of IGF1 , RETN , HP expression across disease phases (EGPA baseline, Cs-remission, Cs-relapse) in macrophages. f Immunofluorescent staining and quantification of IGF1⁺CD68⁺ macrophages in bronchial mucosae (biological replicates; EGPA n = 15, Cs-remission n = 3, Cs-relapse n = 5). Scale bars: 100 μm (upper), 20 μm (lower). g UMAP plots of 11 epithelial cell subsets from combined samples. h Heatmap of relative enrichment (observed/expected Ro/e) of epithelial subtypes across groups and sample types. i Dot plot of reciprocal epithelial ligand-receptor expression across subsets. Interaction pairs linked by color-coded lines; dot size reflects expression fraction, color intensity shows relative expression. j Violin plots of marker gene expression for goblet cell subsets (Goblet-1, Goblet−2) and ionocytes across groups. k Immunofluorescent staining and quantification of MUC5AC⁺ epithelial cells (biological replicates; EGPA n = 10, Cs-remission n = 3, Cs-relapse n = 5). Scale bar: 100 μm. Data presented as median with IQR. f , k Two-sided Kruskal–Wallis test with Dunn’s post-hoc and Bonferroni correction. * P < 0.05, ** P < 0.01, *** P < 0.001; NS, not significant. Exact P values in Supplementary Data . Cs-relapse corticosteroid relapse, Cs-remission corticosteroid remission, DC dendritic cell, DEGs differentially expressed genes, IGF1 insulin-like growth factor 1, MUC5AC mucin 5AC, Ro/e ratio of observed to expected.
    Human Sputum Igf1 Concentration Detection, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human sputum igf1 concentration detection/product/Multi Sciences (Lianke) Biotech Co Ltd
    Average 94 stars, based on 1 article reviews
    human sputum igf1 concentration detection - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    99
    R&D Systems serum igf1 concentration
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Serum Igf1 Concentration, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/serum igf1 concentration/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    serum igf1 concentration - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    93
    Cusabio insulin like growth factor 1 igf 1 concentrations
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Insulin Like Growth Factor 1 Igf 1 Concentrations, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/insulin like growth factor 1 igf 1 concentrations/product/Cusabio
    Average 93 stars, based on 1 article reviews
    insulin like growth factor 1 igf 1 concentrations - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    R&D Systems the elisa kit for serum igf1 concentration (no. mg100)
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    The Elisa Kit For Serum Igf1 Concentration (No. Mg100), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/the elisa kit for serum igf1 concentration (no. mg100)/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    the elisa kit for serum igf1 concentration (no. mg100) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    94
    R&D Systems igf1 concentrations
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Igf1 Concentrations, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf1 concentrations/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    igf1 concentrations - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Thermo Fisher circulating igf1 concentrations
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Circulating Igf1 Concentrations, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/circulating igf1 concentrations/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    circulating igf1 concentrations - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher igf1 circulating concentrations
    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor <t>1(IGF1).</t> A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)
    Igf1 Circulating Concentrations, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igf1 circulating concentrations/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    igf1 circulating concentrations - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    a UMAP plots of 12 macrophage and DC subtypes from baseline and follow-up samples. IGF1 ⁺Macrophage cluster (cluster 3) highlighted. b Volcano plot of DEGs in IGF1 ⁺ macrophages between baseline and follow-up. Upregulated (red), downregulated (blue), stable (grey) genes shown. c Bar plots of top enriched Reactome pathways in IGF1 ⁺ macrophages from DEGs (two-sided Wilcoxon rank-sum test, adjusted P values). Pathway enrichment of top 20 upregulated genes via Enrichr (Reactome_Pathways_2024, hypergeometric test, unadjusted P values). d UMAP plots of key marker gene expression ( HP , IGF1 , RETN ) in macrophage subsets; color intensity reflects normalized UMI counts. e Violin plots of IGF1 , RETN , HP expression across disease phases (EGPA baseline, Cs-remission, Cs-relapse) in macrophages. f Immunofluorescent staining and quantification of IGF1⁺CD68⁺ macrophages in bronchial mucosae (biological replicates; EGPA n = 15, Cs-remission n = 3, Cs-relapse n = 5). Scale bars: 100 μm (upper), 20 μm (lower). g UMAP plots of 11 epithelial cell subsets from combined samples. h Heatmap of relative enrichment (observed/expected Ro/e) of epithelial subtypes across groups and sample types. i Dot plot of reciprocal epithelial ligand-receptor expression across subsets. Interaction pairs linked by color-coded lines; dot size reflects expression fraction, color intensity shows relative expression. j Violin plots of marker gene expression for goblet cell subsets (Goblet-1, Goblet−2) and ionocytes across groups. k Immunofluorescent staining and quantification of MUC5AC⁺ epithelial cells (biological replicates; EGPA n = 10, Cs-remission n = 3, Cs-relapse n = 5). Scale bar: 100 μm. Data presented as median with IQR. f , k Two-sided Kruskal–Wallis test with Dunn’s post-hoc and Bonferroni correction. * P < 0.05, ** P < 0.01, *** P < 0.001; NS, not significant. Exact P values in Supplementary Data . Cs-relapse corticosteroid relapse, Cs-remission corticosteroid remission, DC dendritic cell, DEGs differentially expressed genes, IGF1 insulin-like growth factor 1, MUC5AC mucin 5AC, Ro/e ratio of observed to expected.

    Journal: Nature Communications

    Article Title: Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis

    doi: 10.1038/s41467-025-68104-6

    Figure Lengend Snippet: a UMAP plots of 12 macrophage and DC subtypes from baseline and follow-up samples. IGF1 ⁺Macrophage cluster (cluster 3) highlighted. b Volcano plot of DEGs in IGF1 ⁺ macrophages between baseline and follow-up. Upregulated (red), downregulated (blue), stable (grey) genes shown. c Bar plots of top enriched Reactome pathways in IGF1 ⁺ macrophages from DEGs (two-sided Wilcoxon rank-sum test, adjusted P values). Pathway enrichment of top 20 upregulated genes via Enrichr (Reactome_Pathways_2024, hypergeometric test, unadjusted P values). d UMAP plots of key marker gene expression ( HP , IGF1 , RETN ) in macrophage subsets; color intensity reflects normalized UMI counts. e Violin plots of IGF1 , RETN , HP expression across disease phases (EGPA baseline, Cs-remission, Cs-relapse) in macrophages. f Immunofluorescent staining and quantification of IGF1⁺CD68⁺ macrophages in bronchial mucosae (biological replicates; EGPA n = 15, Cs-remission n = 3, Cs-relapse n = 5). Scale bars: 100 μm (upper), 20 μm (lower). g UMAP plots of 11 epithelial cell subsets from combined samples. h Heatmap of relative enrichment (observed/expected Ro/e) of epithelial subtypes across groups and sample types. i Dot plot of reciprocal epithelial ligand-receptor expression across subsets. Interaction pairs linked by color-coded lines; dot size reflects expression fraction, color intensity shows relative expression. j Violin plots of marker gene expression for goblet cell subsets (Goblet-1, Goblet−2) and ionocytes across groups. k Immunofluorescent staining and quantification of MUC5AC⁺ epithelial cells (biological replicates; EGPA n = 10, Cs-remission n = 3, Cs-relapse n = 5). Scale bar: 100 μm. Data presented as median with IQR. f , k Two-sided Kruskal–Wallis test with Dunn’s post-hoc and Bonferroni correction. * P < 0.05, ** P < 0.01, *** P < 0.001; NS, not significant. Exact P values in Supplementary Data . Cs-relapse corticosteroid relapse, Cs-remission corticosteroid remission, DC dendritic cell, DEGs differentially expressed genes, IGF1 insulin-like growth factor 1, MUC5AC mucin 5AC, Ro/e ratio of observed to expected.

    Article Snippet: For human sputum IGF1 concentration detection, 100uL sputum supernatant was used (Multi Sciences, Cat# EK1131-96).

    Techniques: Marker, Gene Expression, Expressing, Staining

    a Immunofluorescent staining and quantification of IGF1⁺ epithelial cells at bronchial mucosae from control ( n = 6), SEA ( n = 9), EGPA ( n = 10), Cs-remission ( n = 3), and Cs-relapse ( n = 5) groups (biological replicates). Scale bar: 100 μm. b Bar plots of IGF1 concentrations in sputum samples from Control ( n = 13), SEA ( n = 23), and EGPA ( n = 21) (biological replicates). c Schematic of EGPA airway epithelial cells in ALI culture stimulated with IL-13, IL-33, or medium (Control). Bar plots show relative expression of IGF1 , IGF1R , and IGFBP3 , and IGF1 concentrations under different conditions. Data from 3 independent experiments (biological replicates). d Schematic of ALI system with IGF1 stimulation versus control. Representative histological (HE, PAS) and immunofluorescent (MUC5AC with DAPI) staining demonstrate morphological changes and mucin production (goblet hyperplasia) in ALI cultures with medium (Control) or IGF1 stimulation. Scale bars: 50 μm (HE, PAS), 20 μm (MUC5AC). Bar plots of IL-25, IL-33, and TSLP concentrations in culture supernatant at time points (Day 9, 13, 17, 21). Data from 3 independent experiments (biological replicates). e Scatter plot showing positive correlation between eosinophil abundance and IGF1 concentration in sputum from EGPA patients ( n = 21). f Schematic of proposed mechanism where IGF1 promotes goblet hyperplasia and augments T2-mediated inflammation through IGF1-IL25 loop, contributing to disease exacerbation in asthma and EGPA. Data presented as mean ± SD. a – c Two-sided one-way ANOVA with Tukey’s post-hoc test. d Two-sided unpaired t -test. e Two-sided Pearson correlation test. * P < 0.05, ** P < 0.01, *** P < 0.001; NS, not significant. Exact P values in Supplementary Data . ALI air-liquid interface, HE hematoxylin and eosin, IGF1R insulin-like growth factor 1 receptor, IGFBP3 insulin-like growth factor binding protein 3, PAS periodic acid-Schiff, TSLP thymic stromal lymphopoietin.

    Journal: Nature Communications

    Article Title: Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis

    doi: 10.1038/s41467-025-68104-6

    Figure Lengend Snippet: a Immunofluorescent staining and quantification of IGF1⁺ epithelial cells at bronchial mucosae from control ( n = 6), SEA ( n = 9), EGPA ( n = 10), Cs-remission ( n = 3), and Cs-relapse ( n = 5) groups (biological replicates). Scale bar: 100 μm. b Bar plots of IGF1 concentrations in sputum samples from Control ( n = 13), SEA ( n = 23), and EGPA ( n = 21) (biological replicates). c Schematic of EGPA airway epithelial cells in ALI culture stimulated with IL-13, IL-33, or medium (Control). Bar plots show relative expression of IGF1 , IGF1R , and IGFBP3 , and IGF1 concentrations under different conditions. Data from 3 independent experiments (biological replicates). d Schematic of ALI system with IGF1 stimulation versus control. Representative histological (HE, PAS) and immunofluorescent (MUC5AC with DAPI) staining demonstrate morphological changes and mucin production (goblet hyperplasia) in ALI cultures with medium (Control) or IGF1 stimulation. Scale bars: 50 μm (HE, PAS), 20 μm (MUC5AC). Bar plots of IL-25, IL-33, and TSLP concentrations in culture supernatant at time points (Day 9, 13, 17, 21). Data from 3 independent experiments (biological replicates). e Scatter plot showing positive correlation between eosinophil abundance and IGF1 concentration in sputum from EGPA patients ( n = 21). f Schematic of proposed mechanism where IGF1 promotes goblet hyperplasia and augments T2-mediated inflammation through IGF1-IL25 loop, contributing to disease exacerbation in asthma and EGPA. Data presented as mean ± SD. a – c Two-sided one-way ANOVA with Tukey’s post-hoc test. d Two-sided unpaired t -test. e Two-sided Pearson correlation test. * P < 0.05, ** P < 0.01, *** P < 0.001; NS, not significant. Exact P values in Supplementary Data . ALI air-liquid interface, HE hematoxylin and eosin, IGF1R insulin-like growth factor 1 receptor, IGFBP3 insulin-like growth factor binding protein 3, PAS periodic acid-Schiff, TSLP thymic stromal lymphopoietin.

    Article Snippet: For human sputum IGF1 concentration detection, 100uL sputum supernatant was used (Multi Sciences, Cat# EK1131-96).

    Techniques: Staining, Control, Expressing, Concentration Assay, Binding Assay

    a – e Anti-IGF1 treatment reduces eosinophilic inflammation and airway remodeling in IL-5 transgenic mice challenged with HDM and IL-33. Mice were divided into Control (PBS-treated), Model (HDM+IL-33 challenged), and Anti-IGF1 (HDM+IL-33+anti-IGF1 antibody) groups. a Total cell counts in bronchoalveolar lavage fluid (BALF) from control, model, and anti-IGF1-treated groups. b Eosinophil percentage in BALF. c Absolute eosinophil counts in BALF. d IL−25 levels in BALF quantified by ELISA. e Representative histological images of lung sections stained with hematoxylin and eosin (H&E, upper panels) and periodic acid-Schiff (PAS, lower panels), with corresponding inflammation and PAS score quantifications. Scale bar, 100 μm. f – h IGF1R deficiency modulates eosinophilic inflammation and airway remodeling via IL−25 in HDM+IL-33 challenged mice. f Total cell counts in BALF from wild-type (WT, Scgb1a1 -IRES-+/+ Igf1r f/f ), conditional knockout ( Scgb1a1 -IRES-Cre/+ Igf1r f/f , CKO), and CKO mice treated with recombinant IL-25 (rIL-25). All groups were challenged with HDM+IL-33. g Flow cytometric analysis of eosinophils (CD45 + Siglec-F + CD11c - ) in BALF. Representative plots and quantification of eosinophil percentages are shown. h Representative H&E (upper panels) and PAS (lower panels) staining of lung sections from WT, CKO, and CKO+rIL-25 groups, with quantification of inflammation and PAS scores. Scale bar, 100 μm. Statistical analysis: Data are presented as mean ± SD ( n = 5 mice per group). Statistical significance was determined using a two-sided one-way ANOVA with Tukey’s post hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001; NS, not significant. Exact P values and complete test statistics for a – h are provided in Supplementary Data . CKO conditional knockout, HDM house dust mite, rIL-25 recombinant IL-25, WT wild-type.

    Journal: Nature Communications

    Article Title: Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis

    doi: 10.1038/s41467-025-68104-6

    Figure Lengend Snippet: a – e Anti-IGF1 treatment reduces eosinophilic inflammation and airway remodeling in IL-5 transgenic mice challenged with HDM and IL-33. Mice were divided into Control (PBS-treated), Model (HDM+IL-33 challenged), and Anti-IGF1 (HDM+IL-33+anti-IGF1 antibody) groups. a Total cell counts in bronchoalveolar lavage fluid (BALF) from control, model, and anti-IGF1-treated groups. b Eosinophil percentage in BALF. c Absolute eosinophil counts in BALF. d IL−25 levels in BALF quantified by ELISA. e Representative histological images of lung sections stained with hematoxylin and eosin (H&E, upper panels) and periodic acid-Schiff (PAS, lower panels), with corresponding inflammation and PAS score quantifications. Scale bar, 100 μm. f – h IGF1R deficiency modulates eosinophilic inflammation and airway remodeling via IL−25 in HDM+IL-33 challenged mice. f Total cell counts in BALF from wild-type (WT, Scgb1a1 -IRES-+/+ Igf1r f/f ), conditional knockout ( Scgb1a1 -IRES-Cre/+ Igf1r f/f , CKO), and CKO mice treated with recombinant IL-25 (rIL-25). All groups were challenged with HDM+IL-33. g Flow cytometric analysis of eosinophils (CD45 + Siglec-F + CD11c - ) in BALF. Representative plots and quantification of eosinophil percentages are shown. h Representative H&E (upper panels) and PAS (lower panels) staining of lung sections from WT, CKO, and CKO+rIL-25 groups, with quantification of inflammation and PAS scores. Scale bar, 100 μm. Statistical analysis: Data are presented as mean ± SD ( n = 5 mice per group). Statistical significance was determined using a two-sided one-way ANOVA with Tukey’s post hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001; NS, not significant. Exact P values and complete test statistics for a – h are provided in Supplementary Data . CKO conditional knockout, HDM house dust mite, rIL-25 recombinant IL-25, WT wild-type.

    Article Snippet: For human sputum IGF1 concentration detection, 100uL sputum supernatant was used (Multi Sciences, Cat# EK1131-96).

    Techniques: Transgenic Assay, Control, Enzyme-linked Immunosorbent Assay, Staining, Knock-Out, Recombinant

    Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1). A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)

    Journal: Cell communication and signaling : CCS

    Article Title: Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1.

    doi: 10.1186/s12964-024-01472-6

    Figure Lengend Snippet: Fig. 3 Effects of prenatal dexamethasone exposure (PDE) on the fetal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1). A Fetal body weight and intrauterine growth retardation (IUGR) rate (n = 8); (B) Hematoxylin and eosin (H&E) staining of the fetal liver (Scale bar = 500 μm); (C) Ki67-stained nuclei and quantitative analysis (Scale bar = 500 μm); (D) The mRNA expression of hepatic development-related genes (n = 8); (E) Serum CORT level (n = 8); (F) Serum IGF1 level (n = 8); (G) The mRNA expression of IGF1 signaling pathway (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/ kg∙d); PDE(H), prenatal dexamethasone exposure at a high dose (0.8 mg/kg∙d)

    Article Snippet: The ELISA kit for serum IGF1 concentration (No. MG100) was procured from R&D Systems, Inc. in Minneapolis, MN, USA.

    Techniques: Staining, Expressing, Control

    Fig. 4 Effects of prenatal dexamethasone exposure (PDE) on postnatal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1) at postnatal week (PW) 6 and 12. A The mRNA expression of liver development-related genes at PW6 (n = 8); (B) Serum CORT at PW6 (n = 8); (C) Serum IGF1 level at PW6 (n = 8); (D) The mRNA expression of liver IGF1 signaling pathway expression at PW6 (n = 8); (E) Serum CORT with or without unpredictable chronic stress (UCS) at PW12 (n = 8); (F) Serum IGF1 level with or without UCS at PW12 (n = 8); (G) The mRNA expression of liver IGF1 signaling pathway expression with or without UCS at PW12 (n = 8); (H) The mRNA expression of liver development-related genes with or without UCS at PW12 (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/kg∙d)

    Journal: Cell communication and signaling : CCS

    Article Title: Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1.

    doi: 10.1186/s12964-024-01472-6

    Figure Lengend Snippet: Fig. 4 Effects of prenatal dexamethasone exposure (PDE) on postnatal liver development and the levels of corticosterone (CORT) and insulin-like growth factor 1(IGF1) at postnatal week (PW) 6 and 12. A The mRNA expression of liver development-related genes at PW6 (n = 8); (B) Serum CORT at PW6 (n = 8); (C) Serum IGF1 level at PW6 (n = 8); (D) The mRNA expression of liver IGF1 signaling pathway expression at PW6 (n = 8); (E) Serum CORT with or without unpredictable chronic stress (UCS) at PW12 (n = 8); (F) Serum IGF1 level with or without UCS at PW12 (n = 8); (G) The mRNA expression of liver IGF1 signaling pathway expression with or without UCS at PW12 (n = 8); (H) The mRNA expression of liver development-related genes with or without UCS at PW12 (n = 8). Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance; PDE(L), prenatal dexamethasone exposure at a low dose (0.2 mg/kg∙d)

    Article Snippet: The ELISA kit for serum IGF1 concentration (No. MG100) was procured from R&D Systems, Inc. in Minneapolis, MN, USA.

    Techniques: Expressing, Control

    Fig. 6 Effects of prenatal dexamethasone treatment (PDT) on the body weight, serum hepatic function markers, serum cortisol level, and serum insulin-like growth factor 1 (IGF1) level of the male neonates. A Neonatal body weight (n = 18); (B) Serum albumin (ALB) (n = 18); (C) Serum alpha-fetoprotein (AFP) (n = 18); (D) The ratio of ALB to AFP (n = 18); (E) Serum cortisol level (n = 18); (F) Serum IGF1 level (n = 18); (G) The correlation analysis between serum cortisol and IGF1; Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance

    Journal: Cell communication and signaling : CCS

    Article Title: Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1.

    doi: 10.1186/s12964-024-01472-6

    Figure Lengend Snippet: Fig. 6 Effects of prenatal dexamethasone treatment (PDT) on the body weight, serum hepatic function markers, serum cortisol level, and serum insulin-like growth factor 1 (IGF1) level of the male neonates. A Neonatal body weight (n = 18); (B) Serum albumin (ALB) (n = 18); (C) Serum alpha-fetoprotein (AFP) (n = 18); (D) The ratio of ALB to AFP (n = 18); (E) Serum cortisol level (n = 18); (F) Serum IGF1 level (n = 18); (G) The correlation analysis between serum cortisol and IGF1; Mean ± S.E.M. *P < 0.05, **P < 0.01 vs. the control group. NS, no significance

    Article Snippet: The ELISA kit for serum IGF1 concentration (No. MG100) was procured from R&D Systems, Inc. in Minneapolis, MN, USA.

    Techniques: Control

    Fig. 7 Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1. GC, glucocorticoid; GRα, glucocorticoid receptor α; SP1, special protein 1; IGF1, insulin-like growth factor 1; H3K27ac, histone 3 lysine 27 acetylation

    Journal: Cell communication and signaling : CCS

    Article Title: Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1.

    doi: 10.1186/s12964-024-01472-6

    Figure Lengend Snippet: Fig. 7 Dexamethasone exposure during pregnancy triggers metabolic syndrome in offspring via epigenetic alteration of IGF1. GC, glucocorticoid; GRα, glucocorticoid receptor α; SP1, special protein 1; IGF1, insulin-like growth factor 1; H3K27ac, histone 3 lysine 27 acetylation

    Article Snippet: The ELISA kit for serum IGF1 concentration (No. MG100) was procured from R&D Systems, Inc. in Minneapolis, MN, USA.

    Techniques: